Vanda Pharmaceuticals (VNDA)
(Delayed Data from NSDQ)
$4.61 USD
-0.04 (-0.86%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $4.62 +0.01 (0.22%) 7:58 PM ET
4-Sell of 5 4
C Value F Growth A Momentum D VGM
Balance Sheet
Fiscal Year End for Vanda Pharmaceuticals Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 388 | 467 | 433 | 368 | 312 |
Receivables | 34 | 34 | 32 | 30 | 26 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 1 | 1 | 1 | 1 | 1 |
Other Current Assets | 9 | 18 | 12 | 10 | 15 |
Total Current Assets | 433 | 519 | 478 | 409 | 354 |
Net Property & Equipment | 2 | 3 | 3 | 4 | 4 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 10 | 11 | 8 | 0 | 4 |
Deferred Charges | 75 | 74 | 75 | 82 | 88 |
Intangibles | 121 | 19 | 20 | 22 | 23 |
Deposits & Other Assets | 0 | 0 | 0 | 7 | 0 |
Total Assets | 648 | 634 | 594 | 533 | 484 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 38 | 46 | 34 | 32 | 28 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 34 | 32 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 49 | 46 | 40 | 0 | 0 |
Total Current Liabilities | 88 | 91 | 74 | 66 | 60 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 9 | 7 | 4 | 3 | 1 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 104 | 107 | 89 | 80 | 73 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 700 | 686 | 669 | 650 | 631 |
Retained Earnings | -155 | -158 | -164 | -197 | -221 |
Other Equity | 0 | -1 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 545 | 527 | 505 | 453 | 411 |
Total Liabilities & Shareholder's Equity | 648 | 634 | 594 | 533 | 484 |
Total Common Equity | 545 | 527 | 505 | 453 | 411 |
Shares Outstanding | 57.50 | 56.50 | 55.70 | 54.60 | 53.30 |
Book Value Per Share | 9.48 | 9.33 | 9.07 | 8.30 | 7.71 |
Fiscal Year End for Vanda Pharmaceuticals Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 388 | 394 | 388 | 490 | 489 |
Receivables | 42 | 37 | 34 | 29 | 34 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 1 | 2 | 1 | 1 | 1 |
Other Current Assets | 8 | 7 | 9 | 16 | 9 |
Total Current Assets | 439 | 439 | 433 | 537 | 534 |
Net Property & Equipment | 2 | 2 | 2 | 2 | 2 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 9 | 10 | 10 | 10 | 10 |
Deferred Charges | 77 | 75 | 75 | 68 | 70 |
Intangibles | 118 | 119 | 121 | 17 | 18 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 651 | 653 | 648 | 642 | 642 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 40 | 38 | 38 | 33 | 32 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 54 | 56 | 49 | 52 | 55 |
Total Current Liabilities | 94 | 93 | 88 | 85 | 87 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 9 | 9 | 6 | 6 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 109 | 109 | 104 | 99 | 102 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 707 | 704 | 700 | 697 | 694 |
Retained Earnings | -164 | -160 | -155 | -153 | -153 |
Other Equity | 0 | 0 | 0 | -1 | -1 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 543 | 544 | 545 | 543 | 540 |
Total Liabilities & Shareholder's Equity | 651 | 653 | 648 | 642 | 642 |
Total Common Equity | 543 | 544 | 545 | 543 | 540 |
Shares Outstanding | 58.20 | 58.20 | 57.50 | 57.50 | 57.50 |
Book Value Per Share | 9.32 | 9.35 | 9.48 | 9.45 | 9.39 |